RUBINSTEIN JULIE 4

What Happened

• Julie Rubinstein, President and COO of Adaptive Biotechnologies (ADPT), exercised stock options on March 6, 9 and 10, 2026 and sold shares in open-market transactions the same period. She acquired a total of 68,328 shares through option exercises (aggregate exercise cost ~$582,613) and sold 81,342 shares for total gross proceeds of ~$1,211,737. Net proceeds (sales minus exercise cost) were roughly $629,124.
• The exercises were of fully vested options (footnote F5). Several derivative entries showing $0 value reflect the termination/conversion of those options upon exercise.

Key Details

• Transaction dates: March 6, 2026; March 9, 2026; March 10, 2026. Form 4 filed March 10, 2026 (covers the March 6–10 transactions) and appears timely.
• Exercises (acquired): 68,328 shares total — paid ~$582,613 (breakdowns in filing: 14,722 @ $6.55 and 11,881 @ $12.14 on Mar 6 & Mar 9; 14,722 @ $6.55 and 400 @ $12.14 on Mar 10).
• Sales (disposed): 81,342 shares total — weighted-average prices reported, aggregate proceeds ~$1,211,737. Reported weighted averages and per-footnote ranges: sales included prices within $14.83–$15.65, $14.24–$15.15, and $14.22–$15.00 (see footnotes F2–F4 for ranges).
• Plan/authorization: Transactions were executed pursuant to a Rule 10b5-1 trading plan adopted November 18, 2025 (footnote F1).
• Shares owned after the transactions: not disclosed in the data provided for this summary.
• Filing timeliness: Form filed March 10, 2026 — within the SEC’s two-business-day deadline for the listed transaction dates.

Context

• For retail investors: this was an exercise of options followed by open-market sales (effectively a cash-generating event for the insider). The presence of a 10b5-1 plan means the sales were pre-planned and not necessarily a real-time indicator of the insider’s sentiment.
• The zero-dollar derivative lines are standard reporting for options that were converted/terminated on exercise and do not represent separate cash sales.